Dublin, May 12, 2021 (GLOBE NEWSWIRE) — The “Investigation Report on China’s Human Serum Albumin Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
According to this market report, the sales revenue of HSA in the Chinese market increased from CNY2.96 billion in 2016 to CNY4.22 billion in 2020.
Human Serum Albumin (HSA) is made of plasma proteins from human blood, which is mainly used to replace blood volume loss resulting from trauma such as a severe burn or an injury that causes blood loss. It is also used to treat low albumin levels caused by surgery, dialysis, and many other conditions.
Due to the high demand for HSA in the Chinese market, it has become one of the blood products that China allows to import from restricted countries. Currently, there are over 30 manufacturers in the Chinese HSA market. The major manufacturers are Grifols, Baxter, CSL Behring, Aventis Behring, and Shandong Taibang. Among them, Grifols…